Galderma Announces Positive US Pivotal Interim 6-Month Results for EMERVEL Classic Lidocaine Compared to Juvederm Ultra
Galderma Pharma S.A., today announced positive interim 6-month results from an ongoing U.S. pivotal clinical study investigating the safety and efficacy of EMERVEL Classic Lidocaine compared to Juvederm Ultra in the treatment of moderate to severe nasolabial folds. Results from this multi-center, evaluator-blinded and randomized split-face comparative clinical study, which evaluated 170 subjects, demonstrated that, at Week 24, EMERVEL Classic Lidocaine was non-inferior to Juvederm Ultra in terms of efficacy. Both products showed a comparable safety profile. EMERVEL Classic Lidocaine presented a favorable pain score profile. The benefit of pre-incorporated lidocaine in EMERVEL was observed rapidly at the time of injection and the pain relief persisted during the 60 minutes of post-injection follow-up.
"As a principal study investigator for the study I found this HA filler to be easy to inject and control and robust in its character to lift ,” says Gary D. Monheit, MD and Associate Clinical at University of Alabama at Birmingham. “Due to its unique character of excellent filling at multiple levels plus its soft and natural feel it will be a major contribution in our cosmetic toolbox for facial rejuvenation. The patients tolerated this procedure well due to the lidocaine with little side effects and good results ."
These 6-month interim results and the final 12-month results will be subject to further review and future publication in the appropriate medical journal, as well as presentation at future medical conferences. The 6-month data were analyzed by an independent team to protect the integrity of the study and data.
About EMERVEL
EMERVEL is a complete range of five scientifically-advanced and clinically-proven hyaluronic acid dermal fillers including four fillers containing the widely-used anaesthetic lidocaine. Indicated for the treatment of facial lines, lips, contouring and volume loss, the EMERVEL range of fillers carries the Medical Device CE mark 0459. EMERVEL benefits from Optimal Balance TechnologyTM .
Thanks to this manufacturing engineering innovation, each of the EMERVEL fillers possesses the optimal balance between the degree of cross-linking and gel calibration, articulated around a constant hyaluronic acid concentration of 20 mg/mL.
The different variations of the gel calibration and different degrees of cross linking around this constant hyaluronic acid concentration gives way to the optimal gel texture of EMERVEL.
This allows a suitable integration of the gel into the appropriate skin layer, thus enabling the desired aesthetic effect.
As a result, EMERVEL fillers provide excellent combination of immediate and long-lasting aesthetic correction and tolerance whatever the depth, area and volume correction as shown in the previous and current clinical studies.
EMERVEL is part of the aesthetic & corrective portfolio that enables individual beauty by offering an expanding product range to meet the needs from restoring to improving skin’s quality and appearance. The portfolio brings together science-based solutions in dermatology with the heritage of innovative world-renowned aesthetic technology.
About Galderma
Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. A fully-integrated specialty pharmaceutical company, Galderma was founded in 1981 and has nearly 4000 employees (of which 560 are Q-Med employees) in 31 affiliates around the world. In March 2011
Q-Med became a part of Galderma. Q-Med is a global leader in the aesthetic market and develops innovative products for aesthetic, corrective and hospital use. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galderma’s laboratory in Sophia-Antipolis, France, is one of the largest R&D facilities in the world dedicated exclusively to dermatology, now complemented by a state-of-the-art R&D center in Uppsala, Sweden. The company’s extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. Strategic brands include Epiduo, Oracea, Clobex, Differin, Rozex/MetroGel, Silkis/Vectical, Cetaphil, Loceryl, Tri-Luma, Metvix, Azzalure, Dysport, Restylane, Macrolane and Emervel.
*Dysport is a brand of Ipsen
Contact:
Galderma
Annika Öhlin
Tel:
+33 1 58 86 45 37
annika.ohlin@galderma.com
or
Q-Med
Karin
Falck
Tel: +46 70 974 9015
karin.falck@q-med.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mastercard and OCTO Join Forces to Promote Responsible Driving Through Loyalty Programs21.5.2025 18:10:00 CEST | Press release
Thanks to Mastercard’s SessionM platform, OCTO will offer valuable incentives to more responsible drivers while increasing customer engagement and loyalty to insurance companies. Mastercard and OCTO, a global leader in advanced telematics solutions and data analytics services for the insurance and automotive sectors, today announce a collaboration aimed at redefining the interaction between insurance companies and customers by encouraging safer driving behaviors through an innovative loyalty program. The partnership involves the integration of Mastercard’s SessionM – a platform designed to support businesses in managing customer loyalty and engagement – with OCTO’s patented scoring models, which assess driving behavior using either physical devices (black boxes) or digital solutions (apps). This agreement has a dual objective: for drivers, it provides tangible benefits such as discounts on auto, home, and travel insurance, as well as other rewards, in exchange for safe and responsible
Boomi Recognized as a Leader for the 11th Time in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service21.5.2025 17:30:00 CEST | Press release
Boomi Believes Its Leadership in AI, API Management, and Data Management Advancements Will Drive Strong Customer and Partner Momentum Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS), for the 11th consecutive time – the longest in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521105444/en/ In our opinion, Boomi’s continued industry recognition reflects its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in AI agent management, API management, and data management to help enterprises connect everything with one platform and drive intelligent automation at scale. Key advancements include: Launch of Boomi Agentstudio for AI Agent Management: Boomi recently introduced the only full agent life
Textron Aviation Announces Fleet Order for up to 12 Cessna Citation Business Jets From Aerolineas Ejecutivas21.5.2025 17:00:00 CEST | Press release
Textron Aviation today announced it has entered into a purchase agreement with Aerolíneas Ejecutivas (ALE), Mexico’s leading business aviation company, for up to 12 Cessna Citation business jets. ALE will operate the aircraft — a mix of Cessna Citation Latitude, Citation CJ3 Gen2 and Citation CJ3 Gen3 business jets — in its fractional ownership division, MexJet. ALE expects to take delivery of four aircraft, including two Citation Latitudes and two Citation CJ3 Gen2 aircraft, in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521263551/en/ Textron Aviation announces fleet order for up to 12 Cessna Citation business jets from Aerolineas Ejecutivas. (Photo Credit: Textron Aviation) The Cessna Citation business jets are designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are ideal for fractional customers seeking class-leading comfort and performance,” sa
ElastiFlow and Rohde & Schwarz Collaborate To Deliver Unmatched Network Traffic Insights21.5.2025 16:00:00 CEST | Press release
ElastiFlow, a pioneer in the observability space, today announced a strategic partnership with Rohde & Schwarz, one of the world’s leading manufacturers of test and measurement, secure communications, monitoring and network testing, and broadcasting equipment. This collaboration aims to improve network visibility and data enrichment capabilities for enterprises worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521910528/en/ Network flow data, in the form of IPFIX records, is essential for understanding network traffic, detecting anomalies, and ensuring optimized performance and robust security. The new alliance leverages ElastiFlow to enrich IPFIX records from Rohde & Schwarz solutions, transforming raw data into actionable insights. This enables rapid, real-time detection of network events, security threats, and application performance issues. The collaboration allows for deep packet inspection (DPI) technology t
Rauma Marine Constructions:The First Multi-Purpose Corvette Built at Rauma Shipyard Has Been Launched21.5.2025 15:51:00 CEST | Press release
The first multi-purpose corvette built for the Finnish Navy’s pivotal Squadron 2020 project was launched at Rauma shipyard on Wednesday 21 May 2025. This is a significant milestone and an indication of RMC’s ability to successfully realise demanding building projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521270211/en/ The first multi-purpose corvette built for the Finnish Navy’s pivotal Squadron 2020 project was launched at Rauma shipyard in Finland on Wednesday 21 May 2025. Photo by Rauma Marine Constructions. The Squadron 2020 project is proceeding on schedule. The building pace will accelerate as work on the second and subsequent multi-purpose corvettes progresses. The direct employment impact of the Squadron project in Finland is equivalent to more than 3,600 person-years. “We have increased the capacity of Rauma shipyard purposefully while strategically implementing significant investments in the shipyard a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom